Home / Business and Economy / Lilly Inks $475M Deal for MeiraGTx's Gene Therapy for Rare Vision Disorder
Lilly Inks $475M Deal for MeiraGTx's Gene Therapy for Rare Vision Disorder
10 Nov
Summary
- MeiraGTx signs $475M deal with Lilly for gene therapy to treat rare vision loss
- Lilly's latest move to expand eye treatment portfolio and gene therapy focus
- MeiraGTx's therapy aims to restore vision in children with severe genetic disorder
On November 10, 2025, MeiraGTx Holdings announced a significant deal with pharmaceutical giant Eli Lilly, potentially worth over $475 million. The agreement grants Lilly the rights to MeiraGTx's experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.
Under the terms of the deal, MeiraGTx will receive an upfront payment of $75 million, as well as the potential for over $400 million in additional milestone payments. The gene therapy developer will also be eligible for tiered royalties on any licensed products.
This partnership marks Lilly's latest move to tap into the lucrative market for eye treatments and bolster its focus on gene therapies. In October, the company had signed a deal valued at up to $261.7 million to acquire gene therapy developer Adverum Biotechnologies, which is working on an eye injection for wet age-related macular degeneration.
MeiraGTx's experimental therapy, AAV-AIPL1, is being studied to treat one of the most severe forms of Leber congenital amaurosis 4, a genetic disorder caused by mutations in the AIPL1 gene. The therapy is delivered via subretinal injection to children and is designed to restore vision through a one-time administration.
This partnership with Lilly is expected to accelerate the development and commercialization of MeiraGTx's groundbreaking gene therapy, offering hope to patients and their families affected by this devastating condition.
